An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

Summary

The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.

Timeline

Start

2026-06-09

Primary completion

2026-06-30

Completion

2031-02-09

Drugs

Indications